Literature DB >> 10792070

Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis.

T C Chai1, C Zhang, J W Warren, S Keay.   

Abstract

OBJECTIVES: A highly effective treatment for interstitial cystitis (IC) remains elusive. We determined whether sacral third nerve root (S3) percutaneous neurostimulation (PNS) might be effective in relieving symptoms of IC, as well as in normalizing urinary factors that are specifically altered in IC.
METHODS: Six consecutive patients with symptoms and cystoscopic findings compatible with IC underwent 5 days of continuous S3 neurostimulation by way of leads placed percutaneously into the S3 foramen. Patients filled out voiding frequency diaries and pain and urgency questionnaires before PNS and at the end of PNS when the leads were removed. Urine specimens were collected at these two time points and measured for heparin-binding epidermal growth factor-like growth factor (HB-EGF) by enzyme-linked immunosorbent assay and for antiproliferative factor (APF) activity by (3)H-thymidine uptake by normal human bladder urothelial cells.
RESULTS: S3 PNS significantly improved all measured parameters toward normal values. Voiding frequency decreased twofold from 23.1 +/- 4.6 to 10.6 +/- 4.0 voids daily during PNS (P = 0.0001). Pelvic pain on a scale of 1 to 10 decreased from 7.0 +/- 1.6 to 2.3 +/- 3.2 (P = 0.05). Urinary urgency on a scale of 1 to 10 decreased from 6.0 +/- 2.2 to 1.8 +/- 1.7 (P = 0. 02). Urinary HB-EGF concentration increased sevenfold from 1.5 +/- 2. 1 to 11.0 +/- 1.7 ng/mL (P <0.0001), and urinary APF activity decreased from -76.1% +/- 31% to -4.5% +/- 8.8% (P = 0.005).
CONCLUSIONS: S3 PNS significantly decreased symptoms and normalized urinary HB-EGF and APF activity in patients with IC. These results suggest that permanent S3 PNS may be beneficial in treating IC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792070     DOI: 10.1016/s0090-4295(00)00476-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  22 in total

1.  Neuromodulation for the treatment of refractory interstitial cystitis.

Authors:  Kenneth M Peters
Journal:  Rev Urol       Date:  2002

Review 2.  Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction.

Authors:  Jennifer Yonaitis Fariello; K Whitmore
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 3.  Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain.

Authors:  Robert D Mayer; Fred M Howard
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

4.  Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature.

Authors:  Amr Mahran; Gina Baaklini; Daisy Hassani; Hassan A Abolella; Ahmed S Safwat; Mandy Neudecker; Adonis K Hijaz; Sangeeta T Mahajan; Steven W Siegel; Sherif A El-Nashar
Journal:  Int Urogynecol J       Date:  2019-03-14       Impact factor: 2.894

5.  Interstitial cystitis: characterization and management of an enigmatic urologic syndrome.

Authors:  J Curtis Nickel
Journal:  Rev Urol       Date:  2002

Review 6.  Interstitial cystitis and the overlap with overactive bladder.

Authors:  Christopher S Elliott; Christopher K Payne
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

Review 7.  What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?

Authors:  Abhishek Seth; Joel M H Teichman
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

8.  A candidate serum biomarker for bladder pain syndrome/interstitial cystitis.

Authors:  Daniel E Rubio-Diaz; Megan E Pozza; Jordan Dimitrakov; Jason P Gilleran; M Monica Giusti; Judith L Stella; Luis E Rodriguez-Saona; C A Tony Buffington
Journal:  Analyst       Date:  2009-04-16       Impact factor: 4.616

Review 9.  Neuromodulation for Chronic Pelvic Pain.

Authors:  Justina Tam; Charles Loeb; Daniel Grajower; Jason Kim; Steven Weissbart
Journal:  Curr Urol Rep       Date:  2018-03-26       Impact factor: 3.092

10.  Prospective evaluation of candidate urine and cell markers in patients with interstitial cystitis enrolled in a randomized clinical trial of Bacillus Calmette Guerin (BCG).

Authors:  Susan Keay; Jay E Reeder; Kristopher Koch; Chen-Ou Zhang; Daivd Grkovic; Kenneth Peters; Yawei Zhang; John W Kusek; Lee M Nyberg; Christopher K Payne; Kathleen J Propert
Journal:  World J Urol       Date:  2007-08-13       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.